Loading
A phase 2 trial of SHR-A2102 and adebrelimab in triple-negative breast cancer, run by Henan Cancer Hospital, not yet recruiting.
SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06819319 by Henan Cancer Hospital, with a registry enrolment figure of 52 participants, started 2025-06-23 and due to reach its primary completion in 2026-12-31. Interventions recorded: SHR-A2102 ; Adebrelimab injection. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Triple-negative PD-L1-positive breast cancer:". No results are recorded here; the registry entry is the source.
Shares Adebrelimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Adebrelimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.